{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:14:00Z","timestamp":1791335640948,"version":"4.3.1"},"reference-count":21,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2022.1490","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T11:05:49Z","timestamp":1646823949000},"page":"e221490","source":"Crossref","is-referenced-by-count":52,"title":["Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma"],"prefix":"10.1001","volume":"5","author":[{"given":"Tomer","family":"Meirson","sequence":"first","affiliation":[{"name":"Davidoff Cancer Center, Rabin Medical Center\u2013Beilinson Hospital, Petah Tikva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pentimalli","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina e Chirurgia, Libera Universit\u00e0 Mediterranea \u201cGiuseppe Degennaro\u201d, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cerza","sequence":"additional","affiliation":[{"name":"Italian National Agency for Regional Healthcare Services, Rome"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Baglio","sequence":"additional","affiliation":[{"name":"Italian National Agency for Regional Healthcare Services, Rome"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Gray","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Research Group, Trinity St James\u2019s Cancer Institute, Trinity Translational Medicine Institute, Trinity Centre for Health Sciences, St James\u2019s Hospital, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierpaolo","family":"Correale","sequence":"additional","affiliation":[{"name":"Unit of Medical Oncology, Oncology Department, Grand Metropolitan Hospital \u201cBianchi Melacrino Morelli,\u201d Reggio Calabria, Italy"},{"name":"Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Krstic-Demonacos","sequence":"additional","affiliation":[{"name":"Biomedical Research Center, School of Science, Engineering and Environment, University of Salford, Salford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gal","family":"Markel","sequence":"additional","affiliation":[{"name":"Davidoff Cancer Center, Rabin Medical Center\u2013Beilinson Hospital, Petah Tikva, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Giordano","sequence":"additional","affiliation":[{"name":"Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania"},{"name":"Department of Medical Biotechnologies, University of Siena, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bomze","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Mutti","sequence":"additional","affiliation":[{"name":"Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,3,9]]},"reference":[{"issue":"3","key":"zoi220073r1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.v71.3","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"zoi220073r2","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00953-2019","article-title":"ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma.","volume":"55","author":"Scherpereel","year":"2020","journal-title":"Eur Respir J"},{"issue":"14","key":"zoi220073r4","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"issue":"10026","key":"zoi220073r5","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"issue":"10272","key":"zoi220073r6","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"zoi220073r7","first-page":"502","article-title":"FDA approves nivolumab plus ipilimumab for previously untreated unresectable malignant pleural mesothelioma.","volume":"34","author":"Wright","year":"2020","journal-title":"Oncology (Williston Park)"},{"issue":"10","key":"zoi220073r8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.17675","article-title":"Survival-inferred fragility index of phase 3 clinical trials evaluating immune checkpoint inhibitors.","volume":"3","author":"Bomze","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"12","key":"zoi220073r9","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1001\/jamaoncol.2017.2797","article-title":"Interpretability of cancer clinical trial results using restricted mean survival time as an alternative to the hazard ratio.","volume":"3","author":"Pak","year":"2017","journal-title":"JAMA Oncol"},{"issue":"7","key":"zoi220073r10","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1001\/jamaoncol.2020.0628","article-title":"Immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer.","volume":"6","author":"Bomze","year":"2020","journal-title":"JAMA Oncol"},{"key":"zoi220073r11","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2021.04.044","article-title":"Informative censoring of surrogate end-point data in phase 3 oncology trials.","volume":"153","author":"Gilboa","year":"2021","journal-title":"Eur J Cancer"},{"issue":"1","key":"zoi220073r13","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(21)00710-5","article-title":"Radiographic progression-free survival in the ACIS trial for prostate cancer.","volume":"23","author":"Gilboa","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6","key":"zoi220073r14","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1183\/09031936.00000811","article-title":"Predicting survival in malignant mesothelioma.","volume":"38","author":"Musk","year":"2011","journal-title":"Eur Respir J"},{"issue":"2","key":"zoi220073r15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jtho.2015.10.003","article-title":"Contemporary analysis of prognostic factors in patients with unresectable malignant pleural mesothelioma.","volume":"11","author":"Bill\u00e9","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"8","key":"zoi220073r16","first-page":"2073","article-title":"Survival in good performance malignant pleural mesothelioma patients; prognostic factors and predictors of response.","volume":"18","author":"Rahouma","year":"2017","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"zoi220073r17","doi-asserted-by":"crossref","DOI":"10.1515\/pp-2020-0144","article-title":"A review of malignant pleural mesothelioma in a large North East UK pleural centre.","volume":"6","author":"Murphy","year":"2020","journal-title":"Pleura Peritoneum"},{"issue":"2","key":"zoi220073r18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11864-020-00807-y","article-title":"A review of pharmacologic management in the treatment of mesothelioma.","volume":"22","author":"Borrelli","year":"2021","journal-title":"Curr Treat Options Oncol"},{"key":"zoi220073r19","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100625","article-title":"Cost-effectiveness of cancer drugs: comparative analysis of the United States and England.","volume":"29-30","author":"Cherla","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"4","key":"zoi220073r20","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.cllc.2020.01.007","article-title":"Clinical trials eligibility of patients with malignant pleural mesothelioma: use of novel therapies and outcomes.","volume":"21","author":"Lau","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"zoi220073r21","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.638279","article-title":"Is there already a need of reckoning on cancer immunotherapy?","volume":"12","author":"Correale","year":"2021","journal-title":"Front Pharmacol"},{"key":"zoi220073r3","unstructured":"European Medicines Agency. EU\/3\/18\/2006: orphan designation for the treatment of malignant mesothelioma. May 17, 2018. Accessed February 8, 2022.  https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu-3-18-2006?"},{"key":"zoi220073r12","unstructured":"ESMO Daily Reporter. Checkmate 743: immunotherapy in first-line mesothelioma. September 9, 2021. Accessed February 8, 2022. https:\/\/dailyreporter.esmo.org\/esmo-congress-2021\/drug-development\/checkmate-743-reinforces-the-role-of-immunotherapy-in-first-line-mesothelioma"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2789843\/meirson_2022_oi_220073_1646251668.81912.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T11:05:58Z","timestamp":1646823958000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2789843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,9]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.1490","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,9]]}}}